Tech Company M&A Transactions
Corthera Acquisition
On 12/23/2009, Corthera was acquired by Novartis AG. Novartis AG said the transaction price was $120 million.
Transaction Overview
Company Name
Acquired By
Announced On
12/23/2009
Transaction Type
M&A
Amount
$120,000,000
M&A Terms
Under the terms of the transaction, Novartis will acquire all of the outstanding shares of Corthera's stock for USD $120 million. In addition, Corthera's current shareholders will be eligible to receive additional payments of up to USD 500 million that are contingent upon clinical milestones, regulatory approval of relaxin and the achievement of commercialization targets. This transaction, which is subject to customary regulatory approvals, is expected to be completed in the first quarter of 2010.
Company Information
Company Status
Acquired or Merged
Industry
FinTech
Mailing Address
1660 S. Amphlett Blvd. 200
San Mateo, CA 94402
USA
San Mateo, CA 94402
USA
Phone
Website
Email Address
Overview
Corthera Inc., formerly BAS Medical, is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure. Corthera has worldwide rights to develop and commercialize relaxin.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/23/2009: ChaCha Search venture capital transaction
Next: 12/23/2009: 23andMe venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC transactions reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs